Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seroquel XR sNDA For Depression, Anxiety On Track For 1H 2008 Following Positive Phase III Data

This article was originally published in The Pink Sheet Daily

Executive Summary

AstraZeneca tells DAILY that despite the crowded market for depression and anxiety therapies, quetiapine would appeal to patients whose current treatments inadequately control symptoms.

You may also be interested in...



AstraZeneca Submits First Atypical Antipsychotic For Anxiety Indication

Supplemental NDA package for Seroquel XR includes data from four clinical studies, all of which met their primary endpoints.

AstraZeneca Submits First Atypical Antipsychotic For Anxiety Indication

Supplemental NDA package for Seroquel XR includes data from four clinical studies, all of which met their primary endpoints.

AstraZeneca Submits Seroquel XR sNDA For Major Depressive Disorder

Firm looks to expand $4 billion franchise into lucrative MDD market.

Related Content

Topics

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel